Table 3.
Analysis of possible risk factors for the development of moderate or worse hypogammaglobulinemia
| Univariate predictor | HR (95% CI) | P-value |
|---|---|---|
| Age (by decade) | 1.8 (0.9, 3.9) | 0.12 |
| Gender (female) | 0.6 (0.1, 5.3) | 0.69 |
| Race (white) | 1.1 (0.2, 5.5) | 0.90 |
| BMI at enrollment <21 | 1.1 (0.1, 9.1) | 0.92 |
| Pre-transplant BMI <21 | 0.9 (0.1, 7.0) | 0.88 |
| CD4 at enrollment (per 50 cells/μL) | 1.1 (0.96, 1.2) | 0.19 |
| Nadir CD4 at enrollment (per 50 cells/μL) | 1.0 (0.8, 1.2) | 0.94 |
| Detectable HIV RNA at enrollment | 2.1 (0.4, 10.4) | 0.36 |
| HCV infection status (positive) | 0.9 (0.2, 3.8) | 0.89 |
| Combined kidney-liver transplant | 3.5 (0.4, 28.5) | 0.24 |
| Donor age (by decade) | 1.0 (0.6, 1.6) | 0.92 |
| PI-based regimen as initial HAART | 2.7 (0.5, 13.2) | 0.23 |
| Tacrolimus as initial IS (vs. cyclosporine) | 0.7 (0.2, 3.1) | 0.63 |
| Initial mycophenolate mofetil use | 2.4 (0.3–19) | 0.42 |
| HBIg Induction | 1.5 (0.4, 6.2) | 0.60 |
| Basiliximab/Daclizumab induction | 1.2 (0.2, 10.2) | 0.84 |
| Initial val/ganciclovir use | 1.2 (0.1, 9.7) | 0.87 |
| Baseline IgG level (log-scale) | 0.1 (0.002, 2.0) | 0.12 |
| Pre-transplant MELD score | 1.06 (1.002, 1.13) | 0.04 |
| CD4 count* (per 50 cells/μL) | 0.9 (0.8, 1.2) | 0.66 |
| Treated acute rejection* | 3.7 (0.9, 15) | 0.06 |
| Multivariate predictors | HR (95% CI) | P-value |
| Pre-transplant MELD score | 1.08 (1.01, 1.17) | 0.04 |
| Treated acute rejection* | 4.5 (1.1, 19) | 0.04 |
| Age (by decade) | 2.0 (0.97, 4.1) | 0.06 |
*
Time-varying covariate.
HR, hazard ratio; CI, confidence interval; BMI, body mass index; HIV, human immunodeficiency virus; HCV, hepatitis C virus; PI, ?; HAART, highly active anti-retroviral therapy; IS, immunosuppression; HBIg, hepatitis B immunoglobulin; IgG, immunoglobulin G; MELD, model for end-stage liver disease.